- Home
- ESGL vs KLRS Comparison
ESGL vs KLRS Comparison
Compare ESGL & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESGL
- KLRS
- Stock Information
- Founded
- ESGL 1999
- KLRS 2019
- Country
- ESGL Singapore
- KLRS United States
- Employees
- ESGL N/A
- KLRS N/A
- Industry
- ESGL
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ESGL
- KLRS Health Care
- Exchange
- ESGL Nasdaq
- KLRS Nasdaq
- Market Cap
- ESGL 123.1M
- KLRS 129.0M
- IPO Year
- ESGL N/A
- KLRS N/A
- Fundamental
- Price
- ESGL $3.23
- KLRS $2.50
- Analyst Decision
- ESGL
- KLRS Buy
- Analyst Count
- ESGL 0
- KLRS 1
- Target Price
- ESGL N/A
- KLRS N/A
- AVG Volume (30 Days)
- ESGL 84.3K
- KLRS 38.9K
- Earning Date
- ESGL 09-03-2025
- KLRS 08-15-2025
- Dividend Yield
- ESGL N/A
- KLRS N/A
- EPS Growth
- ESGL N/A
- KLRS N/A
- EPS
- ESGL N/A
- KLRS N/A
- Revenue
- ESGL $6,099,784.00
- KLRS N/A
- Revenue This Year
- ESGL N/A
- KLRS N/A
- Revenue Next Year
- ESGL N/A
- KLRS N/A
- P/E Ratio
- ESGL N/A
- KLRS N/A
- Revenue Growth
- ESGL N/A
- KLRS N/A
- 52 Week Low
- ESGL $0.90
- KLRS $2.28
- 52 Week High
- ESGL $3.87
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- ESGL 58.34
- KLRS N/A
- Support Level
- ESGL $2.69
- KLRS N/A
- Resistance Level
- ESGL $3.87
- KLRS N/A
- Average True Range (ATR)
- ESGL 0.30
- KLRS 0.00
- MACD
- ESGL -0.05
- KLRS 0.00
- Stochastic Oscillator
- ESGL 45.87
- KLRS 0.00
About ESGL ESGL Holdings Limited
ESGL Holdings Ltd is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.